Lipoproteins account for part of the broad non-specific antiviral activity of human serum

Antiviral Research

Volumn 42, Issue 3, 1999, Pages

  Singh, Indra P ^a   Chopra, Ashok K ^a   Coppenhaver, Dorian H ^a   Ananatharamaiah, G M ^b   Baron, Samuel ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Antiviral; Apolipoprotein A 1; HDL; Lipoproteins; UTI

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN A1; GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MENGO VIRUS; MINIMUM INHIBITORY CONCENTRATION; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; SERUM; SINDBIS VIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; HUMANS; LIPOPROTEINS, HDL; MENGOVIRUS; NEWCASTLE DISEASE VIRUS; POLIOVIRUS; RNA VIRUSES; SEMLIKI FOREST VIRUS; SINDBIS VIRUS; VACCINIA VIRUS; VERO CELLS; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUS REPLICATION;

EID: 0345535831     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00032-7     Document Type: Conference Paper

References (20)

1. Anantharamaiah G.M., Garber D.W. Chromatographic methods for quantitation of apolipoprotein A-1. Methods Enzymol. 263:1996;267-282.
2. Baron S., McKerlie L. Broadly active inhibitor of viruses spontaneously produced by many cell types in culture. Infect. Immun. 32:1981;449-453.
3. Baron S., Dianzani F., Stanton G.J., Fleischmann W.R. The Interferon System: A Current Review to 1987. 1987;University of Texas Press.
4. Baron S., Niesel D., Singh I.P., McKerlie L., Poast J., Chopra A., Dianziani F., Coppenhaver D.H. Recently described innate broad spectrum virus inhibitors. Microb. Pathol. 7:1989;237-247.
5. Baron S., Chopra A.K., Coppenhaver D.H., Gelman B.B., Poast J., Singh I.P. A defense role for a natural antiviral substance in the nervous system. J. Neuroimmunol. 85:1998;168-175.
6. Falkler W.A. Jr., Diwan A.R., Halstead S.B. A lipid inhibitor of dengue virus in human colostrum and milk; with a note on the absence of anti-dengue secretory antibody. Arch. Virol. 47:1975;3-10.
7. Gerna G., Cattaneo E., Cereda P.M., Revelo M.G., Achilli G. Human coronovirus OC-43 serum inhibitor and neutralizing antibody by a new plaque-reduction assay. Proc. Soc. Exp. Biol. Med. 163:1980;360-366.
8. Hay R., Caputo J., Chen T.R. et al. American Type Culture Collection Catalogue of Cell Lines and Hybridomas. 7th ed. 1992;ATCC, Rockville, MD.
9. Hughes T.K., Blalock J.E., McKerlie M.L., Baron S. Cell-produced viral inhibitor: possible Mechanism of action and chemical composition. Infect. Immun. 32:1981;454-457.
10. Karzon D.T. Non-specific viral inactivating substance (VIS) in human and mammalian sera. J. Immunol. 76:1956;454-463.
11. Kitamura T., Tanaka Y., Sugane M. Studies on a heat-labile variola virus inhibitor in normal sera. II. Further characterization of the inhibitor and its activity. Intervirology. 1:1973;288-296.
12. Kriznova O., Rathova V. Serum inhibitors of myxoviruses. Curr. Top. Microb. Immunol. 47:1969;125-151.
13. Kumar S., McKerlie L.M., Albrecht T.B., Goldman A.S., Baron S. A broadly active viral inhibitor in human and animal organ extracts and body fluids. Proc. Soc. Exp. Biol. Med. 177:1984;104-111.
14. Owens B.J., Anatharamaiah G.M., Kahlon J.B., Srinivas R.V., Compans R.W., Segrest J.P. A polipoprotein A-1 and its amphipathic helix peptide analogoues inhibit human immunodeficiency virus-induced syncitium formation. J. Clin. Invest. 4:1990;1142-1150.
15. Singh I.P., Coppenhaver D.H., Chopra A.K., Baron S. Further characterization of a broad-spectrum antiviral substance in human serum. Immunology. 5:1992;293-303.
16. Singh I.P., Chopra A.K., Coppenhaver D.H., Smith E., Poast J., Baron S. Vertebrate brains contain a broadly active antiviral substance. Antiviral Res. 27:1995;375-388.
17. Srinivas R.V., Birkedal B., Owens R.J., Anantharamaiah G.M., Segrest J.P., Compans R.W. Antiviral effects of lipoprotein A-1 and its synthetic amphipathic peptide analogs. Virology. 176:1990;48-57.
18. Suribaldi L., Seganti L., Orise N., Stasia, Valenti P. Inhibiting activity of human low density lipoproteins toward Sendai virus. Microbiologics. 2:1979;121-128.
19. Thiry L., Cogniaux-LeClark J., Content J., Tack L. Factors which influence inactivation of vesicular stomatitis virus by fresh human serum. Virology. 87:1978;384-393.
20. Yin-Murphy M., Almond J.W. Picrornaviruses. Baron S. Medical Microbiology. 1996;673-683 UTMB, Galveston, TX.